SCHEMBL16640344

SCHEMBL16640344

CC(C)n1c2ccccc2c2ccncc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.46
BCHE P06276 1/20 0.46
MAPT P10636 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
ATM Q13315 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPY5R Q15761 3/20 0.44
NFATC1 O95644 1/20 0.44
GSK3B P49841 1/20 0.44
DYRK1A Q13627 1/20 0.44
MAOA P21397 4/20 0.42
MAOB P27338 4/20 0.42
UTS2R Q9UKP6 1/20 0.42
IDO1 P14902 1/20 0.42
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16640338 0.91 DYRK1A (0.50) ACHEBCHETDP1NPY5RNFATC1
SCHEMBL16640343 0.89 MAOA (0.54) ACHEBCHEMAPTTSHRMAPK1
SCHEMBL16640336 0.87 DYRK1A (0.45) ACHEBCHEMAPTTSHRMAPK1
SCHEMBL14659643 0.86 MAOA (0.41) ACHEMAPTTSHRMAPK1CASP1
SCHEMBL12383079 0.83 MAOA (0.42) ACHEMAOAMAOBIDO1HPGD
SCHEMBL150044 0.82 BCHE (0.59) ACHEBCHEMAPTTSHRMAPK1
SCHEMBL29780042 0.82 BCHE (0.59) ACHEBCHEMAPTTSHRMAPK1
SCHEMBL16099930 0.81 ROCK2 (0.39) ACHEMAPTTSHRMAPK1CASP1
SCHEMBL16640326 0.80 USP2 (0.40) MAPTTSHRMAPK1CASP1CASP7
SCHEMBL16640342 0.80 CDK4 (0.41) MAPTTSHRMAPK1CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 US disclosed
US-20240024318-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 US disclosed
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 US disclosed
US-11679109-B2 SMARCA degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-06-20 US disclosed
US-11542260-B2 Composition of matter for use in organic light-emitting diodes KYULUX, INC. (JP) 2023-01-03 US disclosed
US-11189808-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-11-30 US disclosed
US-20210066613-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES KYULUX, INC. (JP) 2021-03-04 US disclosed
US-20200190100-A1 ORGANIC COMPOUND, AND ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DISPLAY DEVICE INCLUDING THE SAME LG DISPLAY CO., LTD. (KR) 2020-06-18 US disclosed
WO-2019191454-A1 COMPOSITION OF MATTER FOR USE ORGANIC LIGHT-EMITTING DIODES KYULUX, INC. (JP) 2019-10-03 WO disclosed
US-20190233412-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES Kyulux North America, Inc. 2019-08-01 US disclosed
US-20190173019-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES Kyulux North America, Inc. 2019-06-06 US disclosed
US-20190173017-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES Kyulux North America, Inc. 2019-06-06 US disclosed
US-9947881-B2 Platinum complexes and devices ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-17 US disclosed
US-20170012224-A1 PLATINUM COMPLEXES AND DEVICES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2017-01-12 US disclosed
US-9385329-B2 Platinum complexes and devices Arizona Board of Regents on behalf of Arizona State University and Universal Display Corporation (US) 2016-07-05 US disclosed
CN-104755078-A Application of harmine derivatives in preparation of antimicrobial agents XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD 2015-07-01 CN disclosed
US-20150105556-A1 PLATINUM COMPLEXES AND DEVICES ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2015-04-16 US disclosed
CN-103070862-A Application of harmine derivative in preparation of antibacterial drugs XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD 2013-05-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11189808-B2 Platinum complexes and devices OXA1L, OCIAD1, OCIAD2 ACHE 3544/4885BCHE 3371/4885MAPT 1431/4885
US-20190173019-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES CRY2, ALDH1A2, CYBA ACHE 535/4885BCHE 1873/4885MAPT 256/4885
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, TP53, MDM4 ACHE 2690/4885BCHE 2514/4885MAPT 1460/4885
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ACHE 2778/4885BCHE 2634/4885MAPT 2459/4885
US-11542260-B2 Composition of matter for use in organic light-emitting diodes CRY2, NDUFV3, SLCO1B3 ACHE 353/4885BCHE 1528/4885MAPT 166/4885
US-20190233412-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES CRY2, NDUFV3, SLCO1B3 ACHE 353/4885BCHE 1528/4885MAPT 166/4885
US-20240024318-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCA2, SMARCC2 ACHE 2091/4885BCHE 1041/4885MAPT 3823/4885
US-20200190100-A1 ORGANIC COMPOUND, AND ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DISPLAY DEVICE INCLUDING THE SAME OCIAD1, OCIAD2, DRD1 ACHE 2073/4885BCHE 3758/4885MAPT 941/4885
US-20190173017-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES CRY2, ALDH1A2, CYBA ACHE 535/4885BCHE 1873/4885MAPT 256/4885
US-11746120-B2 Stat degraders and uses thereof STAT4, STAT1, STAT3 ACHE 1933/4885BCHE 1281/4885MAPT 3167/4885
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ACHE 2778/4885BCHE 2634/4885MAPT 2459/4885
US-11679109-B2 SMARCA degraders and uses thereof SMARCA1, SMARCA2, SMARCC2 ACHE 2091/4885BCHE 1041/4885MAPT 3823/4885
US-20170012224-A1 PLATINUM COMPLEXES AND DEVICES OXA1L, OCIAD1, OCIAD2 ACHE 3544/4885BCHE 3371/4885MAPT 1431/4885
US-20210066613-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES CRY2, CYBA, NDUFV3 ACHE 652/4885BCHE 2441/4885MAPT 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.